+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sickle Cell Anemia Testing & Screening Market - Global Forecast to 2030- Product Image
Sickle Cell Anemia Testing & Screening Market - Global Forecast to 2030- Product Image
Sale

Sickle Cell Anemia Testing & Screening Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5305523
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sickle Cell Anemia Testing & Screening Market grew from USD 1.07 billion in 2024 to USD 1.21 billion in 2025. It is expected to continue growing at a CAGR of 13.56%, reaching USD 2.29 billion by 2030.

Sickle cell anemia remains a critical global health challenge, affecting millions of individuals and placing significant demands on healthcare systems. An executive summary of the testing and screening landscape illuminates the pioneering technologies, evolving market dynamics, and pressing policy shifts that are shaping today’s environment. As stakeholders-ranging from laboratory directors and clinical practitioners to regulatory authorities and diagnostic developers-seek robust insights, this overview unveils the strategic priorities and emerging trajectories that will determine success in both patient outcomes and commercial performance.

Building on decades of research and recent breakthroughs in molecular diagnostics, the current environment is marked by rapid convergence of point-of-care screening devices, advanced genetic testing protocols, and data-driven decision support tools. Collaboration between public health agencies, academic institutions, and private sector innovators is fostering greater accessibility to early detection, particularly in regions with limited laboratory infrastructure. Against this backdrop, the insights that follow offer a comprehensive perspective on the forces driving the market, the policy implications of forthcoming tariff adjustments, and the segmentation strategies that underpin targeted investment and product development.

Transformative Shifts in the Landscape

Over the past five years, the landscape of sickle cell testing and screening has undergone transformative shifts, driven by breakthroughs in assay sensitivity, miniaturization of diagnostic platforms, and digital integration. Traditional laboratory instruments, once confined to centralized facilities, are being complemented by portable point-of-care devices that enable rapid screening in outpatient clinics, rural healthcare centers, and community outreach programs. This democratization of diagnostics is underpinned by advances in microfluidics and lab-on-a-chip technologies, which deliver reliable hemoglobin polymerization assessments in under ten minutes.

Concurrently, genetic testing has evolved from labor-intensive restriction fragment length polymorphism protocols to high-throughput PCR assays and next-generation sequencing methods, offering unprecedented resolution in identifying sickle cell trait carriers and disease phenotypes. As predictive and prenatal testing solutions gain regulatory clearance, stakeholders are shifting investment toward integrated platforms that bundle molecular analyses, cloud-based data management, and AI-driven interpretation. This convergence of hardware, software, and bioinformatics heralds a new era in which early diagnosis and personalized care pathways become the norm rather than the exception.

Cumulative Impact of United States Tariffs 2025

In 2025, newly implemented United States tariffs on imported diagnostic reagents and instrumentation components have introduced a pivotal inflection point for market participants. Tariffs targeting reagents used in PCR kits and restriction fragment length polymorphism assays have led to a recalibration of supply chains, with manufacturers exploring nearshoring and diversification of raw material sources to mitigate cost pressures. Emerging data indicates that up to 15 percent of component costs have been absorbed by domestic suppliers in response, prompting several global entities to renegotiate supply contracts and invest in tooling for local production.

At the same time, instrument assemblers reliant on precision mechanical parts from affected regions have reported extended lead times, resulting in temporary capacity constraints for point-of-care device rollouts. This has created opportunities for domestic instrument producers to accelerate validation of new prototypes and capture incremental market share. On the regulatory front, incentives offered by federal agencies for onshore manufacturing have spurred public-private collaborations aimed at establishing dedicated manufacturing hubs. By proactively adapting sourcing strategies and investing in localized production capabilities, industry leaders can offset tariff-related headwinds and position themselves for sustained growth.

Key Segmentation Insights

A nuanced understanding of market segmentation is essential for aligning product portfolios with end-user needs and maximizing adoption rates. From the product perspective, the landscape bifurcates into screening devices and testing kits. Screening devices themselves encompass both laboratory instruments used in centralized diagnostics and point-of-care devices deployed at bedside or in community settings. Testing kits further subdivide into blood tests that rely on biochemical assays, genetic tests harnessing molecular methods, and rapid tests designed for immediate on-site results.

Technological segmentation spotlights three core modalities: quantitative blood test analysis platforms, polymerase chain reaction workflows that enable precise genotypic identification, and restriction fragment length polymorphism techniques that remain critical for confirmatory analyses in resource-constrained laboratories. End users range from general and specialty clinics to hospital-based and independent diagnostic laboratories, while public and private hospitals complement the demand footprint alongside research and academic institutes advancing translational science.

Age-based segmentation reveals distinct screening imperatives across newborns, children, adolescents, adults, and elderly populations, each presenting unique challenges in sample collection, counseling, and follow-up care. Furthermore, the type of testing is differentiated among carrier screening, neonatal screening, predictive testing for at-risk individuals, and prenatal diagnostics for expectant mothers. Test configurations span multiplex assays capable of simultaneous detection of multiple hemoglobin variants and single-test formats optimized for high-volume throughput. Finally, testing frequency considerations encompass emergency screenings for acute vaso-occlusive crises, routine screenings in preventive health programs, and specialized screening protocols in clinical trial settings. Disease severity segmentation-mild, moderate, and severe sickle cell presentations-further refines the prioritization of diagnostic solutions and supportive care pathways.

Key Regional Insights

Regional variances in healthcare infrastructure, reimbursement frameworks, and public health priorities significantly influence the adoption of sickle cell testing solutions. In the Americas, established neonatal screening mandates and robust private insurance coverage for genetic tests drive demand for both laboratory-based and point-of-care platforms. Key markets in North America continue to prioritize technological innovation and regulatory harmonization, while Latin American countries focus on expanding rural outreach programs.

Across Europe, the Middle East, and Africa, heterogeneity in healthcare access shapes differentiated strategies. Western European nations emphasize integration of molecular diagnostic protocols within national health services, whereas Middle Eastern markets are scaling investment in genetic counseling and carrier screening initiatives. In Africa, where disease prevalence is highest, partnerships between NGOs, government agencies, and diagnostic developers aim to deploy affordable rapid test kits alongside capacity-building for local laboratories. In the Asia-Pacific region, rising public health budgets and expanding private healthcare networks support adoption of multiplex testing configurations and next-generation sequencing services, particularly in high-burden South Asian countries and rapidly growing Southeast Asian markets.

Key Company Insights

Leading diagnostic and biotechnology companies are driving the evolution of the sickle cell testing market through innovation in assay chemistry, instrumentation, and informatics. Agios Pharmaceuticals, Inc. and Bluebird bio, Inc. are advancing gene-editing research with potential downstream implications for companion diagnostics. Atlas Medical GmbH, Bio-Rad Laboratories, Inc., and Thermo Fisher Scientific Inc. continue to refine instrument platforms, integrating automation and digital interfaces to accelerate throughput and reduce user error.

On the reagent and consumables front, Bio Lab Diagnostics (I) Private Limited, Hemex Health, and HiMedia Laboratories are expanding product lines that cater to both molecular and rapid testing workflows. Clinical laboratory networks such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated reinforce the ecosystem by offering third-party testing services and validation partnerships. Innovators like CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated are collaborating with academic institutes to standardize high-sensitivity genotyping assays, while companies such as PerkinElmer, Inc., Streck, Inc., and Ulta Lab Tests, LLC are streamlining supply chain models for point-of-care deployments.

Emerging players including Anamol Laboratories Pvt. Ltd., Biomedomics Inc., Edvotek Inc., Maternova Inc., Pfizer Inc., PicnicHealth, and Silver Lake Research Corporation are also making strategic inroads through regional partnerships, targeted R&D investments, and focused marketing initiatives that address specific patient cohorts and healthcare settings.

Actionable Recommendations for Industry Leaders

Stakeholders should pursue several strategic imperatives to capitalize on evolving market opportunities. First, investing in modular point-of-care platforms that support both multiplex and single-test configurations will cater to diverse clinical settings and enhance scalability. Second, establishing regional manufacturing partnerships or joint ventures in tariff-impacted jurisdictions can mitigate cost volatility and strengthen supply chain resilience. Third, integrating digital health solutions-such as AI-driven risk stratification and cloud-based result reporting-will differentiate offerings and meet growing demand for data interoperability.

Fourth, collaborating with public health agencies and patient advocacy groups to expand neonatal and carrier screening initiatives will reinforce market penetration and demonstrate social impact. Fifth, pursuing co-development agreements with leading academic and research institutions can accelerate validation of next-generation molecular assays and foster early adoption in clinical trials. Finally, aligning product roadmaps with emerging reimbursement models-particularly value-based care frameworks in North America and Europe-will support predictable revenue streams and facilitate sustainable growth.

Conclusion

Sickle cell testing and screening is poised at a critical juncture characterized by technological innovation, shifting policy landscapes, and intensifying competitive dynamics. By embracing flexible manufacturing strategies, leveraging advanced molecular and point-of-care modalities, and forging collaborative networks across public and private sectors, stakeholders can navigate tariff-induced complexities and accelerate adoption in key markets. A nuanced segmentation approach ensures that solutions are tailored to specific end users, age groups, and disease severities, thereby maximizing clinical utility and commercial success.

Regional insights highlight the necessity of customizing deployment models to local infrastructure and reimbursement norms, while an understanding of the competitive landscape underscores the value of strategic alliances and co-development partnerships. As the market continues to mature, organizations that prioritize both innovation and accessibility will emerge as leaders in delivering life-changing diagnostics for patients worldwide.

Market Segmentation & Coverage

This research report categorizes the Sickle Cell Anemia Testing & Screening Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Screening Devices
    • Laboratory Instruments
    • Point-Of-Care Devices
  • Testing Kits
    • Blood Tests
    • Genetic Tests
    • Rapid Tests
  • Blood Test Analysis
  • PCR
  • Restriction Fragment Length Polymorphism (RFLP)
  • Clinics
    • General Clinics
    • Specialty Clinics
  • Diagnostic Laboratories
    • Hospital-Based Laboratories
    • Independent Laboratories
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Research & Academic Institutes
  • Adolescents
  • Adults
  • Children
  • Elderly
  • Newborns
  • Carrier Testing
  • Neonatal Screening
  • Predictive Testing
  • Prenatal Testing
  • Multiplex Test
  • Single Test
  • Emergency Screening
  • Routine Screening
  • Specialized Screening
  • Mild Sickle Cell Disease
  • Moderate Sickle Cell Disease
  • Severe Sickle Cell Disease

This research report categorizes the Sickle Cell Anemia Testing & Screening Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Sickle Cell Anemia Testing & Screening Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Agios Pharmaceuticals, Inc.
  • Anamol Laboratories Pvt. Ltd.
  • Atlas Medical GmbH
  • Bio Lab Diagnostics (I) Private Limited
  • Bio-Rad Laboratories, Inc.
  • Biomedomics Inc.
  • Bluebird bio, Inc.
  • Calibre Scientific, Inc.
  • CRISPR Therapeutics AG
  • Edvotek Inc.
  • Hemex Health
  • HiMedia Laboratories
  • Laboratory Corporation of America Holdings
  • Maternova Inc.
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • PicnicHealth
  • Quest Diagnostics Incorporated
  • Silver Lake Research Corporation
  • Streck, Inc.
  • Thermo Fisher Scientific Inc.
  • Ulta Lab Tests, LLC
  • Vertex Pharmaceuticals Incorporated

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sickle Cell Anemia Testing & Screening Market, by Product
8.1. Introduction
8.2. Screening Devices
8.2.1. Laboratory Instruments
8.2.2. Point-Of-Care Devices
8.3. Testing Kits
8.3.1. Blood Tests
8.3.2. Genetic Tests
8.3.3. Rapid Tests
9. Sickle Cell Anemia Testing & Screening Market, by Technology
9.1. Introduction
9.2. Blood Test Analysis
9.3. PCR
9.4. Restriction Fragment Length Polymorphism (RFLP)
10. Sickle Cell Anemia Testing & Screening Market, by End-User
10.1. Introduction
10.2. Clinics
10.2.1. General Clinics
10.2.2. Specialty Clinics
10.3. Diagnostic Laboratories
10.3.1. Hospital-Based Laboratories
10.3.2. Independent Laboratories
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
10.5. Research & Academic Institutes
11. Sickle Cell Anemia Testing & Screening Market, by Age Group
11.1. Introduction
11.2. Adolescents
11.3. Adults
11.4. Children
11.5. Elderly
11.6. Newborns
12. Sickle Cell Anemia Testing & Screening Market, by Type Of Testing
12.1. Introduction
12.2. Carrier Testing
12.3. Neonatal Screening
12.4. Predictive Testing
12.5. Prenatal Testing
13. Sickle Cell Anemia Testing & Screening Market, by Test Configuration
13.1. Introduction
13.2. Multiplex Test
13.3. Single Test
14. Sickle Cell Anemia Testing & Screening Market, by Testing Frequency
14.1. Introduction
14.2. Emergency Screening
14.3. Routine Screening
14.4. Specialized Screening
15. Sickle Cell Anemia Testing & Screening Market, by Disease Severity
15.1. Introduction
15.2. Mild Sickle Cell Disease
15.3. Moderate Sickle Cell Disease
15.4. Severe Sickle Cell Disease
16. Americas Sickle Cell Anemia Testing & Screening Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Sickle Cell Anemia Testing & Screening Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Sickle Cell Anemia Testing & Screening Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Agios Pharmaceuticals, Inc.
19.3.2. Anamol Laboratories Pvt. Ltd.
19.3.3. Atlas Medical GmbH
19.3.4. Bio Lab Diagnostics (I) Private Limited
19.3.5. Bio-Rad Laboratories, Inc.
19.3.6. Biomedomics Inc.
19.3.7. Bluebird bio, Inc.
19.3.8. Calibre Scientific, Inc.
19.3.9. CRISPR Therapeutics AG
19.3.10. Edvotek Inc.
19.3.11. Hemex Health
19.3.12. HiMedia Laboratories
19.3.13. Laboratory Corporation of America Holdings
19.3.14. Maternova Inc.
19.3.15. PerkinElmer, Inc.
19.3.16. Pfizer Inc.
19.3.17. PicnicHealth
19.3.18. Quest Diagnostics Incorporated
19.3.19. Silver Lake Research Corporation
19.3.20. Streck, Inc.
19.3.21. Thermo Fisher Scientific Inc.
19.3.22. Ulta Lab Tests, LLC
19.3.23. Vertex Pharmaceuticals Incorporated
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET MULTI-CURRENCY
FIGURE 2. SICKLE CELL ANEMIA TESTING & SCREENING MARKET MULTI-LANGUAGE
FIGURE 3. SICKLE CELL ANEMIA TESTING & SCREENING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2030 (%)
FIGURE 22. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LABORATORY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD TEST ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP), BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEWBORNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEONATAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MULTIPLEX TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SINGLE TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY EMERGENCY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ROUTINE SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SPECIALIZED SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MILD SICKLE CELL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MODERATE SICKLE CELL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SEVERE SICKLE CELL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 96. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 97. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 98. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 99. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 102. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 103. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 104. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 105. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 106. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 107. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 108. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 109. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 110. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 111. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 116. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 118. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 119. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 120. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 121. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 163. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 164. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 165. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 166. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 169. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 170. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 171. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 173. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 174. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 175. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 176. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 178. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 179. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 180. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 182. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 183. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 184. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 185. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 186. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 187. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 188. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 191. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 192. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 193. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 195. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 202. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 203. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 204. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 205. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 208. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 209. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 210. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 211. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 212. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 213. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 214. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 222. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 223. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 225. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 226. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 227. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 228. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 229. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 230. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 231. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 234. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 235. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 236. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 238. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 239. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 240. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 241. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 242. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 243. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 244. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 247. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 248. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 249. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 250. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 251. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 252. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 253. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 254. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 255. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 256. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 257. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 258. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 261. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 265. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 267. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 268. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 269. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 270. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 272. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
TABLE 277. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST CONFIGURATION, 2018-2030 (USD MILLION)
TABLE 278. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING FREQUENCY, 2018-2030 (USD MILLION)
TABLE 279. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 280. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 281. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SCREENING DEVICES, 2018-2030 (USD MILLION)
TABLE 282. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TESTING KITS, 2018-2030 (USD MILLION)
TABLE 283. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 284. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 286. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY D

Companies Mentioned

  • Agios Pharmaceuticals, Inc.
  • Anamol Laboratories Pvt. Ltd.
  • Atlas Medical GmbH
  • Bio Lab Diagnostics (I) Private Limited
  • Bio-Rad Laboratories, Inc.
  • Biomedomics Inc.
  • Bluebird bio, Inc.
  • Calibre Scientific, Inc.
  • CRISPR Therapeutics AG
  • Edvotek Inc.
  • Hemex Health
  • HiMedia Laboratories
  • Laboratory Corporation of America Holdings
  • Maternova Inc.
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • PicnicHealth
  • Quest Diagnostics Incorporated
  • Silver Lake Research Corporation
  • Streck, Inc.
  • Thermo Fisher Scientific Inc.
  • Ulta Lab Tests, LLC
  • Vertex Pharmaceuticals Incorporated

Methodology

Loading
LOADING...

Related Topics

Related Reports

Sickle Cell Anemia Testing And Screening Market Size, Share & Trends Analysis Report By Technology (Hemoglobin Electrophoresis, Point-of-Care Tests), By Age Group, By Sector Type, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Sickle Cell Anemia Testing And Screening Market Size, Share & Trends Analysis Report By Technology (Hemoglobin Electrophoresis, Point-of-Care Tests), By Age Group, By Sector Type, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Sickle Cell Anemia Testing and Screening Market by Technology, by Age Group, End-User, and By Region - Product Image

Sickle Cell Anemia Testing and Screening Market by Technology, by Age Group, End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
Sickle Cell Anemia Testing and Screening - Global Strategic Business Report - Product Image

Sickle Cell Anemia Testing and Screening - Global Strategic Business Report

  • Report
  • 62 Pages
  • Global
From
Renal Anemia Market - Product Image

Renal Anemia Market

  • Report
  • 250 Pages
  • Global
From
Iron Deficiency Anemia Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Iron Deficiency Anemia Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.